Coherus Oncology, Inc.(CHRS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,828 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CHRS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Coherus Oncology, Inc. (CHRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CHRS at 42.9/100 on a 32-signal composite quality model, placing it at rank #1,828 of 2,879 stocks — the bottom half of the AI-ranked universe. CHRS scores in the top quartile across balance sheet strength (99.7), profitability (98.2), institutional flow (83.9). Areas of concern include revenue growth (1.7) and free cash flow (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Coherus Oncology, Inc. reports quarterly revenue of $12.3M, net income of $-38.3M, free cash flow of $-57.9M. Top institutional holders of CHRS by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Samsara BioCapital,, based on the most recent SEC filings. CHRS trades on the Nasdaq exchange and files with the SEC under CIK 1512762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coherus Oncology, Inc. directly from SEC EDGAR. Coherus Oncology, Inc.'s 13F Pro composite quality score has ranged between 8 and 53 since 2025, currently 42.9 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.
Revenue
Q1 2026
$12.3M
Net Income
Q1 2026
$-38.3M
Free Cash Flow
Q1 2026
$-57.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+59.8% YoYNet Income
+489.4% YoYOperating Income
+9.3% YoYEPS (Diluted)
+472.0% YoYTotal Assets
-42.4% YoYTotal Debt
Op. Cash Flow
-577.7% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M +59.8% | $26.4M -87.5% | $211.0M -55.6% | $475.8M +33.6% | $356.1M | $0.00 |
| Net Income | $168.0M +489.4% | $28.5M +109.8% | $-291.8M -320.6% | $132.2M +47.2% | $89.8M +142.9% | $-209.3M |
| Operating Income | $-181.1M +9.3% | $-199.7M +22.3% | $-256.9M -264.3% | $156.3M +45.1% | $107.8M +152.7% | $-204.4M |
| EPS (Diluted) | $1.43 +472.0% | $0.25 +106.6% | $-3.76 -332.1% | $1.62 +31.7% | $1.23 +138.2% | $-3.22 |
| Total Assets | $258.3M -42.4% | $448.5M -6.7% | $480.8M -42.9% | $841.6M +105.8% | $408.9M +311.1% | $99.5M |
| Total Debt | — | — | — | — | $73.7M | $0.00 |
| Operating Cash Flow | $-138.5M -577.7% | $-20.4M +91.5% | $-241.1M -256.4% | $154.1M +443.6% | $28.4M +117.8% | $-159.3M |
Get alerted when CHRS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Coherus Oncology, Inc. including:
Top Institutional Holders of CHRS
BlackRock, Inc.
$17.5M10,365,074 shVANGUARD CAPITAL MANAGEMENT LLC
$9.2M5,452,762 shSamsara BioCapital, LLC
$5.8M3,428,571 shGEODE CAPITAL MANAGEMENT, LLC
$5.3M3,121,578 shKohlberg Kravis Roberts & Co. L.P.
$5.1M3,036,076 shSTATE STREET CORP
$3.9M2,325,859 shTWO SIGMA INVESTMENTS, LP
$3.9M2,302,001 shAlyeska Investment Group, L.P.
$3.8M2,250,000 shCM Management, LLC
$3.5M2,100,000 shTANG CAPITAL MANAGEMENT LLC
$3.2M1,886,748 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $17.5M | 10,365,074 |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.2M | 5,452,762 |
| Samsara BioCapital, LLC | $5.8M | 3,428,571 |
| GEODE CAPITAL MANAGEMENT, LLC | $5.3M | 3,121,578 |
| Kohlberg Kravis Roberts & Co. L.P. | $5.1M | 3,036,076 |
| STATE STREET CORP | $3.9M | 2,325,859 |
| TWO SIGMA INVESTMENTS, LP | $3.9M | 2,302,001 |
| Alyeska Investment Group, L.P. | $3.8M | 2,250,000 |
| CM Management, LLC | $3.5M | 2,100,000 |
| TANG CAPITAL MANAGEMENT LLC | $3.2M | 1,886,748 |
More Healthcare Companies
View all Healthcare →Put CHRS on your watchlist
Track score changes the day Coherus Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CHRS a good stock to buy?
13F Pro's AI-powered analysis of Coherus Oncology, Inc. (CHRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CHRS are available on the CHRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CHRS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CHRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Coherus Oncology, Inc.'s investment landscape.